Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings

Introduction:Androgen deprivation therapy is the first line of treatment for advanced prostate cancer (PC). However, PC progressed in most patients when it becomes resistant to castration. This study aimed to investigate the possible role of interleukin-23 (IL-23), a cytokine expressed in various ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cihan Gündoğan, Nurhan Ergül, Huriye Serin, Ediz Beyhan, Burçak Yılmaz, Tevfik Fikret Çermik
Formato:	article
Lenguaje:	EN
Publicado:	Galenos Yayinevi 2021
Materias:	interleukin-23 prostate adenocarcinoma ga-68 psma-11 pet/ct Medicine R
Acceso en línea:	https://doaj.org/article/2afe482c1b2845f1b120ccbc4fe57550
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2afe482c1b2845f1b120ccbc4fe57550
record_format	dspace
spelling	oai:doaj.org-article:2afe482c1b2845f1b120ccbc4fe575502021-11-23T10:25:25ZPrognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings2619-97932148-094X10.4274/imj.galenos.2021.70487https://doaj.org/article/2afe482c1b2845f1b120ccbc4fe575502021-11-01T00:00:00Z http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/prognostic-role-of-nterleukin-23-in-prostate-adeno/49717 https://doaj.org/toc/2619-9793https://doaj.org/toc/2148-094XIntroduction:Androgen deprivation therapy is the first line of treatment for advanced prostate cancer (PC). However, PC progressed in most patients when it becomes resistant to castration. This study aimed to investigate the possible role of interleukin-23 (IL-23), a cytokine expressed in various cancers, in the development of resistance to castration and prognosis in PC.Methods:Twenty-three patients with PC were consecutively enrolled in the study to undergo gallium-68 (Ga-68) prostatespecific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT). Among those patients, 13 were newly diagnosed as treatment-naive (ND), while 10 were evaluated for disease progression under hormonotheraphy. Before PET/CT, 5 mL of venous blood samples was obtained from the study participants. Serum levels of IL-23 were determined by enzyme-linked immunosorbent assay using an IL-23 receptor kit. The relationship of ND and castration-resistant (CR) groups with serum IL-23 level and the correlation of the rate of lymph node involvement, skeletal and distant metastasis Gleason scores, prostate-specific antigen (PSA) levels, and maximum standardized uptake value (SUVmax) of the prostate gland with IL-23 levels were analyzed.Results:Ga-68 PSMA PET/CT revealed that 13 (56.5%) patients had skeletal metastases, 10 (43.5%) had non-pelvic nodal metastasis, and 3 (13%) had distant-organ metastasis. The difference between the serum IL-23 levels of the ND group and the CR group was not significant (p=0.664). The IL-23 levels were not significantly different between patients with and without metastatic disease. Further, no significant association was found among age, IL-23 levels, and total PSA levels as well as primary tumor SUVmax and serum IL-23 levelsConclusion:Although a significant correlation was found between serum IL-23 levels and the development of castration resistance, the metastatic stage and SUVmax were not proven decisively. Thus, it can be assumed that IL-23 has no major role in the development of castration resistance and prognosis in PC.Cihan GündoğanNurhan ErgülHuriye SerinEdiz BeyhanBurçak YılmazTevfik Fikret ÇermikGalenos Yayineviarticleinterleukin-23prostate adenocarcinomaga-68 psma-11 pet/ctMedicineRENİstanbul Medical Journal, Vol 22, Iss 4, Pp 320-325 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	interleukin-23 prostate adenocarcinoma ga-68 psma-11 pet/ct Medicine R
spellingShingle	interleukin-23 prostate adenocarcinoma ga-68 psma-11 pet/ct Medicine R Cihan Gündoğan Nurhan Ergül Huriye Serin Ediz Beyhan Burçak Yılmaz Tevfik Fikret Çermik Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
description	Introduction:Androgen deprivation therapy is the first line of treatment for advanced prostate cancer (PC). However, PC progressed in most patients when it becomes resistant to castration. This study aimed to investigate the possible role of interleukin-23 (IL-23), a cytokine expressed in various cancers, in the development of resistance to castration and prognosis in PC.Methods:Twenty-three patients with PC were consecutively enrolled in the study to undergo gallium-68 (Ga-68) prostatespecific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT). Among those patients, 13 were newly diagnosed as treatment-naive (ND), while 10 were evaluated for disease progression under hormonotheraphy. Before PET/CT, 5 mL of venous blood samples was obtained from the study participants. Serum levels of IL-23 were determined by enzyme-linked immunosorbent assay using an IL-23 receptor kit. The relationship of ND and castration-resistant (CR) groups with serum IL-23 level and the correlation of the rate of lymph node involvement, skeletal and distant metastasis Gleason scores, prostate-specific antigen (PSA) levels, and maximum standardized uptake value (SUVmax) of the prostate gland with IL-23 levels were analyzed.Results:Ga-68 PSMA PET/CT revealed that 13 (56.5%) patients had skeletal metastases, 10 (43.5%) had non-pelvic nodal metastasis, and 3 (13%) had distant-organ metastasis. The difference between the serum IL-23 levels of the ND group and the CR group was not significant (p=0.664). The IL-23 levels were not significantly different between patients with and without metastatic disease. Further, no significant association was found among age, IL-23 levels, and total PSA levels as well as primary tumor SUVmax and serum IL-23 levelsConclusion:Although a significant correlation was found between serum IL-23 levels and the development of castration resistance, the metastatic stage and SUVmax were not proven decisively. Thus, it can be assumed that IL-23 has no major role in the development of castration resistance and prognosis in PC.
format	article
author	Cihan Gündoğan Nurhan Ergül Huriye Serin Ediz Beyhan Burçak Yılmaz Tevfik Fikret Çermik
author_facet	Cihan Gündoğan Nurhan Ergül Huriye Serin Ediz Beyhan Burçak Yılmaz Tevfik Fikret Çermik
author_sort	Cihan Gündoğan
title	Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
title_short	Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
title_full	Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
title_fullStr	Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
title_full_unstemmed	Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
title_sort	prognostic role of interleukin-23 in prostate adenocarcinoma: comparison with gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography findings
publisher	Galenos Yayinevi
publishDate	2021
url	https://doaj.org/article/2afe482c1b2845f1b120ccbc4fe57550
work_keys_str_mv	AT cihangundogan prognosticroleofinterleukin23inprostateadenocarcinomacomparisonwithgallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyfindings AT nurhanergul prognosticroleofinterleukin23inprostateadenocarcinomacomparisonwithgallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyfindings AT huriyeserin prognosticroleofinterleukin23inprostateadenocarcinomacomparisonwithgallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyfindings AT edizbeyhan prognosticroleofinterleukin23inprostateadenocarcinomacomparisonwithgallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyfindings AT burcakyılmaz prognosticroleofinterleukin23inprostateadenocarcinomacomparisonwithgallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyfindings AT tevfikfikretcermik prognosticroleofinterleukin23inprostateadenocarcinomacomparisonwithgallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyfindings
_version_	1718416754304090112

Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings

Ejemplares similares